Stock DNA
Pharmaceuticals & Biotechnology
USD 3,056 Million (Small Cap)
NA
0.00%
-21.41
-999,999.00%
-27.26
Total Returns (Price + Dividend) 
Amneal Pharmaceuticals, Inc. for the last several years.
Risk Adjusted Returns v/s 
News

Amneal Pharmaceuticals Hits New 52-Week High of $10.70
Amneal Pharmaceuticals, Inc. achieved a new 52-week high of USD 10.70 on October 30, 2025, reflecting a 45.99% growth over the past year. The company, with a market capitalization of USD 3,056 million, operates in the Pharmaceuticals & Biotechnology industry and exhibits unique financial metrics.
Read More
Amneal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance
Amneal Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The company’s stock price has shown resilience, with a notable year-to-date return of 33.21%. Over the past year, it has outperformed the S&P 500, reflecting its strong recovery and growth trajectory in the pharmaceuticals sector.
Read MoreIs Amneal Pharmaceuticals, Inc. technically bullish or bearish?
As of 3 October 2025, the technical trend for Amneal Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting the positive trend. Bollinger Bands also indicate a bullish stance on both weekly and monthly time frames. However, the weekly RSI is bearish, suggesting some short-term weakness, while the monthly RSI shows no signal. The daily moving averages are bullish, reinforcing the overall positive outlook. Dow Theory indicates a mildly bullish trend on the monthly chart, with no trend on the weekly. Additionally, the KST is bullish weekly but mildly bearish monthly, and the OBV shows a mildly bullish stance monthly. In terms of performance, Amneal has outperformed the S&P 500 across all multi-period returns, notably with a 375.23% return over three years compared to the S&P 500's 82.57%. Overall, the current technical stance is bu...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 61 Schemes (14.75%)
Held by 107 Foreign Institutions (4.31%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 3.23% vs 17.16% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 111.90% vs -43.43% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 16.73% vs 8.20% in Dec 2023
YoY Growth in year ended Dec 2024 is -51.75% vs 80.89% in Dec 2023






